Luye Pharma Group Ltd. is a high-risk pharmaceutical company based in China, specializing in the development and sale of pharmaceutical products. The company focuses on creating drugs for cancer, cardiovascular, gastrointestinal, and central nervous system conditions. With a Risk Rating Score of 31.0, Luye Pharma Group Ltd. prioritizes environmental, sustainability, and governance practices. The company generates the most revenue from oncology drugs and distributes its products worldwide, including in Asia, Europe, and the United States. Organized into different product segments, Luye Pharma Group Ltd. is a leading player in the pharmaceutical industry.